Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | FABP4 | P15090 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21733660 | 0.93 | HCRTR2 (0.32) | HCRTR2SMN1; SMN2LTB4R2KMT2APDE2A | |
| SCHEMBL28490711 | 0.89 | TUBB3 (0.33) | MAPTKMT2AALDH1A1KDM4EHPGD | |
| SCHEMBL21733931 | 0.83 | PDE2A (0.33) | LTB4R2PDE2AFABP4 | |
| SCHEMBL21733627 | 0.83 | TP53 (0.33) | HCRTR2SMN1; SMN2LTB4R2ALDH1A1HTT | |
| SCHEMBL24854893 | 0.82 | KDM4E (0.32) | MAPTKMT2AALDH1A1KDM4EHPGD | |
| SCHEMBL21733844 | 0.82 | POLB (0.33) | HCRTR2MAPTKMT2APDE2AALDH1A1 | |
| SCHEMBL21733471 | 0.81 | ALDH1A1 (0.33) | SMN1; SMN2MAPTKMT2APDE2AALDH1A1 | |
| SCHEMBL21733858 | 0.80 | PDE10A (0.33) | SMN1; SMN2MAPTKMT2AALDH1A1KDM4E | |
| SCHEMBL21733838 | 0.79 | TP53 (0.32) | HCRTR2LTB4R2ALDH1A1TP53USP2 | |
| SCHEMBL26268266 | 0.79 | TP53 (0.32) | HCRTR2LTB4R2ALDH1A1TP53USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760744-B2 | Fused ring compounds | GENENTECH, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| WO-2020035031-A1 | FUSED RING COMPOUNDS | GENENTECH, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11760744-B2 | Fused ring compounds | KRAS, NRAS, HRAS | HCRTR2 4007/4885SMN1; SMN2 3687/4885MAPT 3269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.